Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07142252 · ClinicalTrials.gov registry record · Phase 2
Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus
A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT07142252 is a Phase 2 study that is actively recruiting participants, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 66 participants.
The verdict
NCT07142252, a Phase 2 study, is actively recruiting participants, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
This Phase 2 study is a 2-arm, multi-center, double-masked (masking of the participant, care provider and investigator), placebo-controlled, 2:1 randomized trial design in new onset T1D participants (within 100 days of diagnosis). Participants will be administered rezpegaldesleukin/placebo once every 14 days over 26 weeks with an additional 6-month follow-up period.
Interventions
- DRUG Placebo
- DRUG Rezpegaldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2026-05-14 |
| Est. Completion | 2028-05-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07142252
The ClinicalTrials.gov registry entry for NCT07142252 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07142252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07142252 about?
NCT07142252 is a clinical study titled "Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus". This Phase 2 study is a 2-arm, multi-center, double-masked (masking of the participant, care provider and investigator), placebo-controlled, 2:1 randomized trial design in new onset T1D participants (within 100 days of diagnosis). Participants will be administered rezpegaldesleukin/placebo once ever...
What is the current status of trial NCT07142252?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2026-05-14. Estimated completion is 2028-05-25.
What interventions are being tested in trial NCT07142252?
The interventions under investigation include: Placebo (DRUG), Rezpegaldesleukin (DRUG).
Who is sponsoring clinical trial NCT07142252?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.